Rockwell Medical Technologies, Inc., an integrated biopharmaceutical company, engages in the manufacture, sale, and distribution of hemodialysis concentrates and other ancillary medical products for the treatment of patients with end stage renal disease in the United States and internationally. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company develops generic version of calcitriol, a vitamin D analogue for the treatment of secondary hyperparathyroidism. Its lead drug candidate is soluble ferric pyrophosphate, an element used in the formation of new red blood cells for the treatment of iron deficiency in anemia dialysis patients. Rockwell Medical Technologies, Inc. sells its products to hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors. The company was founded in 1995 and is based in Wixom, Michigan.